ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important June 6 Deadline in Securities Class Action - ABBVPRNewsWire • 06/02/22
ABBVIE INC. (NYSE: ABBV) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against AbbVie Inc. (NYSE: ABBV)PRNewsWire • 06/01/22
AbbVie Inc. (ABBV) Presents at Bernstein 38th Annual Strategic Decisions ConferenceSeeking Alpha • 06/01/22
AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022PRNewsWire • 06/01/22
MONDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in AbbVie Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 06/01/22
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of AbbVie Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 6, 2022 - (NYSE: ABBV)PRNewsWire • 06/01/22
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages AbbVie Inc. Investors With Losses to Secure Counsel Before Important June 6 Deadline in Securities Class Action - ABBVNewsfile Corp • 05/31/22
AbbVie Class Action: Levi & Korsinsky Reminds AbbVie Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 6, 2022 - ABBVNewsfile Corp • 05/30/22
Shareholder Alert: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AbbVie Inc. - ABBVNewsfile Corp • 05/28/22
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important June 6 Deadline in Securities Class Action - ABBVNewsfile Corp • 05/28/22
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in AbbVie Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 05/27/22
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative ColitisPRNewsWire • 05/27/22
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn's DiseasePRNewsWire • 05/27/22
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AbbVie Inc. Investors With Losses to Secure Counsel Before Important June 6 Deadline in Securities Class Action - ABBVNewsfile Corp • 05/26/22
AbbVie, Inc. Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds ABBV Investors of Securities Fraud Class Action Lawsuit Filed On Their BehalfPRNewsWire • 05/26/22
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in AbbVie Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 05/26/22